Literature DB >> 32991749

Reversal of sepsis-induced T cell dysfunction: OX-40 to the rescue?

Edward R Sherwood1,2, David L Williams2,3.   

Abstract

The study of Unsinger and colleagues provide important insights into OX40 mediated immunotherapy as a potential approach for the treatment of sepsis induced immune suppression. ©2020 Society for Leukocyte Biology.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32991749      PMCID： PMC7987777          DOI： 10.1002/JLB.3CE0720-468

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN： 0741-5400            Impact factor:   4.962


  10 in total

1.  The search for effective therapy for sepsis: back to the drawing board?

Authors:  Derek C Angus
Journal:  JAMA       Date:  2011-12-21       Impact factor: 56.272

Review 2.  OX40: Structure and function - What questions remain?

Authors:  Jane Willoughby; Jordana Griffiths; Ivo Tews; Mark S Cragg
Journal:  Mol Immunol       Date:  2017-01-13       Impact factor: 4.407

3.  Sepsis-induced apoptosis leads to active suppression of delayed-type hypersensitivity by CD8+ regulatory T cells through a TRAIL-dependent mechanism.

Authors:  Jacqueline Unsinger; Hirotaka Kazama; Jacqueline S McDonough; Thomas S Griffith; Richard S Hotchkiss; Thomas A Ferguson
Journal:  J Immunol       Date:  2010-05-12       Impact factor: 5.422

4.  Why have clinical trials in sepsis failed?

Authors:  John C Marshall
Journal:  Trends Mol Med       Date:  2014-02-24       Impact factor: 11.951

5.  Immunosuppression and Secondary Infection in Sepsis: Part, Not All, of the Story.

Authors:  Derek C Angus; Steven Opal
Journal:  JAMA       Date:  2016-04-12       Impact factor: 56.272

6.  OX40 ligand regulates inflammation and mortality in the innate immune response to sepsis.

Authors:  Matthew Karulf; Ann Kelly; Andrew D Weinberg; Jeffrey A Gold
Journal:  J Immunol       Date:  2010-09-15       Impact factor: 5.422

7.  Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations.

Authors:  Carolin Fleischmann; André Scherag; Neill K J Adhikari; Christiane S Hartog; Thomas Tsaganos; Peter Schlattmann; Derek C Angus; Konrad Reinhart
Journal:  Am J Respir Crit Care Med       Date:  2016-02-01       Impact factor: 21.405

8.  Evidence for Persistent Immune Suppression in Patients Who Develop Chronic Critical Illness After Sepsis.

Authors:  Julie A Stortz; Tyler J Murphy; Steven L Raymond; Juan C Mira; Ricardo Ungaro; Marvin L Dirain; Dina C Nacionales; Tyler J Loftus; Zhongkai Wang; Tezcan Ozrazgat-Baslanti; Gabriela L Ghita; Babette A Brumback; Alicia M Mohr; Azra Bihorac; Philip A Efron; Lyle L Moldawer; Frederick A Moore; Scott C Brakenridge
Journal:  Shock       Date:  2018-03       Impact factor: 3.454

9.  A critical role for OX40 in T cell-mediated immunopathology during lung viral infection.

Authors:  Ian R Humphreys; Gerhard Walzl; Lorna Edwards; Aaron Rae; Sue Hill; Tracy Hussell
Journal:  J Exp Med       Date:  2003-10-20       Impact factor: 14.307

10.  Late mortality after sepsis: propensity matched cohort study.

Authors:  Hallie C Prescott; John J Osterholzer; Kenneth M Langa; Derek C Angus; Theodore J Iwashyna
Journal:  BMJ       Date:  2016-05-17
  10 in total
  1 in total

1.  Severity of Sepsis Determines the Degree of Impairment Observed in Circulatory and Tissue-Resident Memory CD8 T Cell Populations.

Authors:  Steven J Moioffer; Derek B Danahy; Stephanie van de Wall; Isaac J Jensen; Frances V Sjaastad; Scott M Anthony; John T Harty; Thomas S Griffith; Vladimir P Badovinac
Journal:  J Immunol       Date:  2021-09-03       Impact factor: 5.426
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.